Cited time in webofscience Cited time in scopus

Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERB alpha Antagonist as a Therapy for Mood Disorders in Parkinson's Disease

Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERB alpha Antagonist as a Therapy for Mood Disorders in Parkinson's Disease
Kim, JeongahPark, InahJang, SangwonChoi, MijungKim, DoyeonSun, WoongChoe, YoungshikChoi, Ji-WoongMoon, CheilPark, Sung HoChoe, Han KyoungKim, Kyungjin
Issued Date
Neurotherapeutics, v.19, no.2, pp.592 - 607
Author Keywords
Parkinson's diseaseSundowning syndromeCircadian mood regulationRev-erb alphaNurr1Dopaminergic neuronal loss
Parkinson's disease is a neurodegenerative disease characterized by progressive dopaminergic neuronal loss. Motor deficits experienced by patients with Parkinson's disease are well documented, but non-motor symptoms, including mood disorders associated with circadian disturbances, are also frequent features. One common phenomenon is "sundowning syndrome," which is characterized by the occurrence of neuropsychiatric symptoms at a specific time (dusk), causing severe quality of life challenges. This study aimed to elucidate the underlying mechanisms of sundowning syndrome in Parkinson's disease and their molecular links with the circadian clock. We demonstrated that 6-hydroxydopamine (6-OHDA)-lesioned mice, as Parkinson's disease mouse model, exhibit increased depression- and anxiety-like behaviors only at dawn (the equivalent of dusk in human). Administration of REV-ERB alpha antagonist, SR8278, exerted antidepressant and anxiolytic effects in a circadian time-dependent manner in 6-OHDA-lesioned mice and restored the circadian rhythm of mood-related behaviors. 6-OHDA-lesion altered DAergic-specific Rev-erb alpha and Nurr1 transcription, and atypical binding activities of REV-ERB alpha and NURR1, which are upstream nuclear receptors for the discrete tyrosine hydroxylase promoter region. SR8278 treatment restored the binding activities of REV-ERB alpha and NURR1 to the tyrosine hydroxylase promoter and the induction of enrichment of the R/N motif, recognized by REV-ERB alpha and NURR1, as revealed by ATAC-sequencing; therefore, tyrosine hydroxylase expression was elevated in the ventral tegmental area of 6-OHDA-injected mice, especially at dawn. These results indicate that REV-ERB alpha is a potential therapeutic target, and its antagonist, SR8278, is a potential drug for mood disorders related to circadian disturbances, namely sundowning syndrome, in Parkinson's disease. © 2022, The American Society for Experimental NeuroTherapeutics, Inc.
Related Researcher
  • 최지웅 Choi, Ji-Woong 전기전자컴퓨터공학과
  • Research Interests Communication System; Signal Processing; Communication Circuit Design; 생체 신호 통신 및 신호 처리; 뇌-기계 인터페이스(BMI); 차세대 교차계층 통신 및 신호 처리; 5G 모바일 통신
Files in This Item:

There are no files associated with this item.

Appears in Collections:
Department of Brain Sciences Laboratory of Animal Behavior and Circadian rhythm 1. Journal Articles
Department of Brain Sciences Laboratory of Chemical Senses 1. Journal Articles
Department of Electrical Engineering and Computer Science CSP(Communication and Signal Processing) Lab 1. Journal Articles


  • twitter
  • facebook
  • mendeley

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.